Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

78 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Next generation flow cytometry for MRD detection in patients with AL amyloidosis.
Kastritis E, Kostopoulos IV, Theodorakakou F, Fotiou D, Gavriatopoulou M, Migkou M, Tselegkidi MI, Roussou M, Papathoma A, Eleutherakis-Papaioakovou E, Dialoupi I, Kanellias N, Ntalianis A, Rousakis P, Trougakos IP, Tsitsilonis O, Gakiopoulou C, Terpos E, Dimopoulos MA. Kastritis E, et al. Among authors: ntalianis a. Amyloid. 2021 Mar;28(1):19-23. doi: 10.1080/13506129.2020.1802713. Epub 2020 Aug 12. Amyloid. 2021. PMID: 32783569
Utilization and tolerance of beta-blockers among patients with AL amyloidosis.
Briasoulis A, Stamatelopoulos K, Petropoulos I, Patras R, Theodorakakou F, Gavriatopoulou M, Ntalianis A, Dimopoulos MA, Kastritis E. Briasoulis A, et al. Among authors: ntalianis a. Amyloid. 2022 Mar;29(1):31-37. doi: 10.1080/13506129.2021.1981281. Epub 2021 Sep 22. Amyloid. 2022. PMID: 34549676
Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis.
Kastritis E, Gavriatopoulou M, Roussou M, Bagratuni T, Migkou M, Fotiou D, Ziogas DC, Kanellias N, Eleutherakis-Papaiakovou E, Dialoupi I, Ntanasis-Stathopoulos I, Spyropoulou-Vlachou M, Psimenou E, Gakiopoulou H, Marinaki S, Papadopoulou E, Ntalianis A, Terpos E, Dimopoulos MA. Kastritis E, et al. Among authors: ntalianis a. Amyloid. 2018 Dec;25(4):234-241. doi: 10.1080/13506129.2018.1540410. Epub 2019 Jan 20. Amyloid. 2018. PMID: 30663408
Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone.
Kastritis E, Dialoupi I, Gavriatopoulou M, Roussou M, Kanellias N, Fotiou D, Ntanasis-Stathopoulos I, Papadopoulou E, Ziogas DC, Stamatelopoulos K, Manios E, Ntalianis A, Eleutherakis-Papaiakovou E, Papanikolaou A, Migkou M, Papanota AM, Gakiopoulou H, Psimenou E, Tselegkidi MI, Tsitsilonis O, Kostopoulos I, Terpos E, Dimopoulos MA. Kastritis E, et al. Among authors: ntalianis a. Blood Adv. 2019 Oct 22;3(20):3002-3009. doi: 10.1182/bloodadvances.2019000147. Blood Adv. 2019. PMID: 31648323 Free PMC article.
Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis.
Kastritis E, Fotiou D, Theodorakakou F, Dialoupi I, Migkou M, Roussou M, Karatrasoglou EA, Tselegkidi MI, Ntalianis A, Kanellias N, Eleutherakis-Papaiakovou E, Ntanasis-Stathopoulos I, Gakiopoulou C, Papanikolaou A, Papathoma A, Spyropoulou-Vlachou M, Psimenou E, Stamatelopoulos K, Gavriatopoulou M, Terpos E, Dimopoulos MA. Kastritis E, et al. Among authors: ntalianis a. Amyloid. 2021 Mar;28(1):3-11. doi: 10.1080/13506129.2020.1798224. Epub 2020 Jul 27. Amyloid. 2021. PMID: 32713209
Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib.
Kastritis E, Gavriatopoulou M, Roussou M, Fotiou D, Ziogas DC, Migkou M, Eleutherakis-Papaiakovou E, Panagiotidis I, Kanellias N, Psimenou E, Papadopoulou E, Pamboucas C, Manios E, Gakiopoulou H, Ntalianis A, Tasidou A, Giannouli S, Terpos E, Dimopoulos MA. Kastritis E, et al. Among authors: ntalianis a. Blood Cancer J. 2017 Jun 16;7(6):e570. doi: 10.1038/bcj.2017.47. Blood Cancer J. 2017. PMID: 28622303 Free PMC article.
Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies.
Kastritis E, Roussou M, Gavriatopoulou M, Migkou M, Kalapanida D, Pamboucas C, Kaldara E, Ntalianis A, Psimenou E, Toumanidis ST, Tasidou A, Terpos E, Dimopoulos MA. Kastritis E, et al. Among authors: ntalianis a. Am J Hematol. 2015 Apr;90(4):E60-5. doi: 10.1002/ajh.23936. Epub 2015 Mar 9. Am J Hematol. 2015. PMID: 25580702 Free article.
Cardiac and renal complications of carfilzomib in patients with multiple myeloma.
Dimopoulos MA, Roussou M, Gavriatopoulou M, Psimenou E, Ziogas D, Eleutherakis-Papaiakovou E, Fotiou D, Migkou M, Kanellias N, Panagiotidis I, Ntalianis A, Papadopoulou E, Stamatelopoulos K, Manios E, Pamboukas C, Kontogiannis S, Terpos E, Kastritis E. Dimopoulos MA, et al. Among authors: ntalianis a. Blood Adv. 2017 Feb 27;1(7):449-454. doi: 10.1182/bloodadvances.2016003269. eCollection 2017 Feb 28. Blood Adv. 2017. PMID: 29296960 Free PMC article.
Cardiac amyloidosis: in search of the ideal diagnostic tool.
Mavrogeni SI, Vartela V, Ntalianis A, Vretou R, Ikonomidis I, Tselegkidou M, Paraskevaidis I, Markousis-Mavrogenis G, Noutsias M, Rigopoulos A, Kolovou G, Kastritis E. Mavrogeni SI, et al. Among authors: ntalianis a. Herz. 2021 Apr;46(Suppl 1):9-14. doi: 10.1007/s00059-019-04871-5. Epub 2019 Dec 3. Herz. 2021. PMID: 31796976 Review. English.
78 results